Class: Calcineurin Inhibitor
Dosage Forms. Ophthalmic Emulsion: 0.5%
Common FDA Label Indication, Dosing, and Titration.
1. Keratoconjunctivitis sicca, when associated ocular inflammation results in scanty tear production: 1 drop in affected eye(s) q12h
Off-Label Uses. None
MOA. Ocular inflammation associated with keratoconjunctivitis sicca results in reduced tear production. Cyclosporin binds to cyclophylin, which inhibits the antigenic response of helper T lymphocytes which reduces the production of interleukin 2 and suppresses interferon-gamma. Inhibition of the immune response limits inflammation.
Drug Characteristics: Cyclosporine Ophthalmic
Medication Safety Issues: Cyclosporine Ophthalmic
Drug Interactions: Cyclosporine Ophthalmic. None known
Adverse Reactions: Cyclosporine Ophthalmic
Efficacy Monitoring Parameters. Improved tear production.
Toxicity Monitoring Parameters. Severe burning of the eye, active ocular infection.
Key Patient Counseling Points. This medicine comes in single-use packages. After you open a single-use package, use the medicine right away. Mix the medicine well just before using it. To do this, turn the single-use package upside down a few times. Remove contact lenses before using this medicine. Wait at least 15 min before inserting contact lenses after using the medicine.
Clinical Pearls. Not for use in children younger than 16 y.